Vistagen (NASDAQ: VTGN) appointed Angel S. Angelov as chief medical officer, effective May 18, 2026, according to a company statement.

Angelov brings two decades of experience in clinical development and medical affairs. He most recently served as chief medical officer at Theranica, a neuromodulation therapeutics company. His previous roles include managing director at ANG Holding, vice president and head of medical affairs at Karuna Therapeutics, and vice president and clinical leader for the VMAT-2 franchise at Neurocrine Biosciences.

Angelov has also held positions at CollaGenex, Indivior, Novartis, NuPathe, and Teva, along with faculty positions at Thomas Jefferson University and Temple University. He earned his medical degree from Sofia Medical University and completed residency and fellowship training at Thomas Jefferson University. He also holds an MBA from the Wharton School at the University of Pennsylvania.

Angelov is board certified in psychiatry and holds a diplomate from the American Board of Psychiatry and Neurology, along with an active Pennsylvania medical license.

The compensation committee of Vistagen's board of directors granted Angelov an incentive stock option to purchase up to 150,000 shares of common stock at an exercise price of $0.5955 per share. The option vests 25% after one year, with the remainder vesting monthly over 36 months thereafter.

Vistagen develops intranasal neurocircuitry-focused product candidates called pherines for neuropsychiatric and women's health conditions. The company's pipeline includes fasedienol in Phase 3 development for social anxiety disorder, itruvone for major depressive disorder, and refisolone for menopausal hot flashes.